Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advantage Novo As Victoza Gets CV Benefit Okay in Europe

Executive Summary

Victoza is the only drug in the GLP-1 class in Europe to have a label that includes the prevention of CV events (and only the second antidiabetic after Boehringer Ingelheim/Lilly’s SGLT2 inhibitor Jardiance) which will help slow down market share loss to Lilly's Trulicity.

You may also be interested in...



Novo Nordisk Says More To Victoza Outcomes Benefit Than A GLP-1 Class Effect

Novo Nordisk's ESC satellite symposium on heels of FDA approval of CV event prevention claim for Victoza highlights differences compared to Sanofi's competing Lyxumia, which failed an outcomes study.

Novo Nordisk: Semaglutide Heralds Commercial Dawn Of Obesity Market

The Danish group expects its experimental GLP-1 semaglutide to prove so effective and safe in fighting obesity that it will spur commercial viability for medical treatment of the condition.

Semaglutide Should Transform Novo Nordisk's Prospects, CSO Says

Novo Nordisk's investigational GLP-1 agonist semaglutide promises to elevate the Danish group's product offering and market position, its CSO says in an interview with Scrip.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC099226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel